XNASEOLS
Market cap687mUSD
Dec 24, Last price
10.85USD
1D
0.09%
1Q
-32.48%
IPO
-6.95%
Name
Evolus Inc
Chart & Performance
P/E
—
P/S
3.40
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.46%
Rev. gr., 5y
%
Revenues
202m
+35.98%
Net income
-62m
L-17.10%
CFO
-34m
L+287.60%
Earnings
Mar 05, 2025
Profile
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 202,085 35.98% | 148,616 49.10% | 99,673 76.29% | ||||||
Cost of revenue | 233,059 | 202,469 | 45,598 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (30,974) | (53,853) | 54,075 | ||||||
NOPBT Margin | 54.25% | ||||||||
Operating Taxes | 176 | 95 | 42 | ||||||
Tax Rate | 0.08% | ||||||||
NOPAT | (31,150) | (53,948) | 54,033 | ||||||
Net income | (61,685) -17.10% | (74,412) 58.97% | (46,810) -71.28% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 224 | 539 | 103,777 | ||||||
BB yield | -0.04% | -0.13% | -32.03% | ||||||
| Debt | |||||||||
Debt current | 2,754 | 1,320 | 1,265 | ||||||
Long-term debt | 131,356 | 74,423 | 76,999 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 36,200 | 41,074 | 44,426 | ||||||
Net debt | 71,272 | 21,821 | (67,992) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (34,008) | (8,774) | (33,388) | ||||||
CAPEX | (473) | (2,939) | (970) | ||||||
Cash from investing activities | (1,627) | (1,391) | 4,030 | ||||||
Cash from financing activities | 44,641 | (1,516) | 73,052 | ||||||
FCF | (36,792) | (56,109) | 54,651 | ||||||
| Balance | |||||||||
Cash | 62,838 | 53,922 | 146,256 | ||||||
Long term investments | |||||||||
Excess cash | 52,734 | 46,491 | 141,272 | ||||||
Stockholders' equity | (559,405) | (497,630) | (422,881) | ||||||
Invested Capital | 702,839 | 630,402 | 119,168 | ||||||
ROIC | 34.24% | ||||||||
ROCE | 26.89% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 56,919 | 56,065 | 49,773 | ||||||
Price | 10.53 40.21% | 7.51 15.36% | 6.51 93.75% | ||||||
Market cap | 599,354 42.35% | 421,050 29.94% | 324,023 185.84% | ||||||
EV | 670,626 | 442,871 | 256,031 | ||||||
EBITDA | (25,107) | (49,356) | 60,389 | ||||||
EV/EBITDA | 4.24 | ||||||||
Interest | 13,832 | 9,097 | 1,396 | ||||||
Interest/NOPBT | 2.58% | ||||||||